Skip to main content
Clinical Trials/NCT05435911
NCT05435911
Completed
Not Applicable

Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil Compared to Propofol-based Total Intravenous Anesthesia in Patients Undergoing Breast Cancer Surgery: a Randomized Controlled Trial

Seoul National University Hospital1 site in 1 country66 target enrollmentAugust 2, 2022

Overview

Phase
Not Applicable
Intervention
REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Conditions
Recovery
Sponsor
Seoul National University Hospital
Enrollment
66
Locations
1
Primary Endpoint
Time to eye opening (minute)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This prospective randomized trial aims to compare recovery time from discontinuation of remimazolam followed by flumazenil administration vs. propofol-based total intravenous anesthesia in patients undergoing breast cancer surgery.

Detailed Description

Adult patients undergoing breast cancer surgery are randomized to receive either remimazolam with flumazenil or propofol-based total intravenous anesthesia. When the surgery is ended, anesthetic agents are discontinued. The study's primary outcome is a comparison of the time to the first eye-opening response to the doctor's command from the discontinuation of anesthetic agents between the groups. Secondary outcomes include the time from anesthetics off to extubation/discharge from operating room (OR), BIS score at eye-opening/extubation/discharge from OR, the incidence of emergence agitation at OR, the PAT score, the modified Aldrete score, modified OAA/S (Observers Assessment of Alertness/Sedation Scale) after PACU administration. In addition, the investigators investigate postoperative pain score at 10/20/30 minutes and postoperative nausea and vomiting after PACU administration, Korean version of quality of recovery-15 in postoperative 24 hours, postoperative pain score and postoperative nausea and vomiting, postoperative opioid consumption in postoperative 24 hours.

Registry
clinicaltrials.gov
Start Date
August 2, 2022
End Date
December 21, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yunseok Jeon

Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult patient, age \>19, scheduled for breast cancer surgery under general anesthesia

Exclusion Criteria

  • Patients who are not alert before procedure
  • Day surgery
  • Hemodynamicaly unstable patients before procedure
  • Patients with history of neromuscular disease or drug use affecting neuromuscular function.
  • Patients with history of adverse reaction of allergic reaction to study drugs
  • Patients who are anticipated to be unable to remove supraglottic airway or endotracheal tube due to severe dyspnea or need for mechanical ventilatory support
  • Use of sedatives (anxiolytics, psychoactive medication, antidepressants, hypnotics) within 24 h
  • Known galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
  • Alcohol or drug dependence
  • Organic brain disorder

Arms & Interventions

Remimazolam with flumazenil

Patients allocated to remimazolam with flumazenil group receive remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.

Intervention: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]

Remimazolam with flumazenil

Patients allocated to remimazolam with flumazenil group receive remimazolam as the main anesthetics during general anesthesia and then flumazenil administration at the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.

Intervention: Flumazenil

Propofol-based total intravenous anesthesia

Patients allocated to the propofol-based total intravenous anesthesia group receive propofol as the main anesthetics during general anesthesia until the end of anesthesia. Remifentanil continuous infusion can be used for hemodynamic stability and analgesia.

Intervention: Propofol

Outcomes

Primary Outcomes

Time to eye opening (minute)

Time Frame: 20 minutes after anesthesia emergence

The time to the first eye-opening response to the doctor's command from the discontinuation of anesthetic agents

Secondary Outcomes

  • Incidence of emergence agitation at operating room (n(%))(Time Frame: 20 minutes after anesthesia emergence)
  • The modified Observers Assessment of Alertness/Sedation Scale (Score)(30 minutes after post anaestheisa care unit adminstration)
  • Postoperative Pain (score)(upto 24 hours)
  • Postoperative opioid consumption (The number of analgesic use)(upto 24 hours)
  • Bispectral index score (Score)(During 20 minutes after anesthesia emergence (3 point : Time from anesthetics off to eye opening/extubation/discharge from operating room))
  • The modified Aldrete score (Score)(30 minutes after post anaestheisa care unit adminstration)
  • Time to emergence (minutes)(20 minutes after anesthesia emergence)
  • Postoperative nausea and vomiting (The incidence of PONV, n(%))(from post anaestheisa care unit administation to post anaestheisa care unit discharge (during 30-40 minutes, upto 1 hours))
  • Postoperative quality of recovery (score)(upto 24 hours)

Study Sites (1)

Loading locations...

Similar Trials